ABCB1 and plasma cell myeloma: In multiple myeloma, overexpression of ABCB1/MDR1 actively pumps the proteasome inhibitor Carfilzomib out of cells via its ATP-dependent efflux pump function, markedly reducing intracellular drug concentration and thereby driving therapeutic resistance [27].